YBX1 and breast carcinoma: A study showed that the YBX1 phosphorylation inhibitors including TAS0612 (multikinase inhibitor) and everolimus (rapamycin complex 1 inhibitor) mitigated antiestrogen resistance in breast cancer (Shibata et al., 2020).